Truqap can be a kinase inhibitor that works by blocking pathways that support the cancer cells survive and develop, so lowers cancer progress. Truqap is from a class of medicines known as an AKT inhibitor. Truqap obtained FDA acceptance on November 17, 2023, right after optimistic final results through the https://resmetirom24578.blogacep.com/40034908/trastuzumab-deruxtecan-for-dummies